首页> 外文OA文献 >Tumour-marker levels and prognosis in malignant teratoma of the testis.
【2h】

Tumour-marker levels and prognosis in malignant teratoma of the testis.

机译:睾丸恶性畸胎瘤的肿瘤标志物水平和预后。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The effect of 6 putative prognostic factors on survival was studied in patients with Stages III and IV malignant teratoma of the testis. Differences between survival curves were tested for statistical significance. A diameter greater than 5 cm in the largest tumour mass, and greater than 8 pulmonary metastases were adverse prognostic factors (P = 0.004 and 0.008 respectively). Patients with malignant teratoma, trophoblastic, fared worse than those with malignant teratoma, undifferentiated, and malignant teratoma, intermediate (P = 0.011 and 0.023 respectively). Previous chemotherapy or radiotherapy had no significant effect. Serum alpha-foetoprotein (AFP) above 10(3) MRC u/ml and serum beta subunit of human chorionic gonadotrophin (hCG) above 10(5) miu/ml, were found to predict a poor prognosis (P = 0.010 and 0.001 respectively). A combination of measurements of the tumour markers gave the most consistent indication of prognosis, in that patients with either AFP greater than 10(3) MRC u/ml or hCG greater than 10(5) miu/ml, or both, fared much worse than those with neither factor (P = 0.001). Serum concentrations of AFP and hCG should be stated in reports of treatment of testicular teratoma in order to provide a basis for comparison with other series. Regular and frequent measurements of these markers are appropriate throughout the clinical management of patients with malignant teratoma.
机译:在三期和四期睾丸恶性畸胎瘤患者中研究了6种预后因素对生存的影响。测试了生存曲线之间的差异的统计学意义。最大肿瘤块直径大于5 cm,肺转移大于8个是不良预后因素(分别为P = 0.004和0.008)。滋养细胞恶性畸胎瘤患者的病情比未分化恶性畸胎瘤和中度恶性畸胎瘤的患者差(分别为P = 0.011和0.023)。先前的化学疗法或放射疗法均无明显效果。血清α-甲胎蛋白(AFP)高于10(3)MRC u / ml和人绒毛膜促性腺激素(hCG)的血清β亚单位高于10(5)miu / ml,可预测不良预后(分别为P = 0.010和0.001) )。结合肿瘤标志物的测量可最一致地预后,因为AFP大于10(3)MRC u / ml或hCG大于10(5)miu / ml或两者均差很多比那些都没有的因素(P = 0.001)。在睾丸畸胎瘤的治疗报告中应说明血清AFP和hCG的含量,以提供与其他系列比较的基础。在恶性畸胎瘤患者的整个临床治疗过程中,定期和频繁地测量这些标志物是适当的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号